Skip to main content

Table 1 Characteristics of the entire cohort and of the PS-matched cohort at baseline

From: Fluticasone furoate/Vilanterol 92/22 μg once-a-day vs Beclomethasone dipropionate/Formoterol 100/6 μg b.I.D.: a 12-month comparison of outcomes in mild-to-moderate asthma

  Overall cohort PS-matched cohort
  Group A Group B Difference
Group B – Group A
Group A Group B Difference
Group B – Group A
n 77 40   40 40  
Males (n)
(%)
26
(33.8%)
15
(37.5%)
−11
(−3.80%)
15
(37.5%)
15
(37.5%)
0
Mean Age (years)
(±s.e.)
51.87
(±1.60)
50.2
(±2.43)
−1.69 49.40
(±2.05)
50.2
(±2.43)
0.78
Mean FEV1% predicted
(±s.e.)
82.2
(±1.14)
81.9
(±2.00)
−0.30 82.40
(±1.6)
81.9
(±2.00)
−0.47
Comorbidities
(% of patients)
37.7% 42.5% −4.80% 42.5% 42.5% 0%
  1. Forced expiratory volume in 1 s, predicted values (FEV1%)
  2. Group A: patients treated with Beclomethasone dipropionate/Formoterol 100/6 μg b.i.d
  3. Group B: patients treated with Fluticasone furoate/Vilanterol 92/22 μg once-a-day